Dernièrement…

Welcome @AmoebaNature as a featured exhibitor at the BioSolutions Conference & Expo!

Amoéba is an innovative #greentech company providing the industry with disruptive & sustainable solutions for key resource treatment. Learn more at http://ow.ly/icPi50Mzv8N

#BioSolutions

📣 Communiqué de presse : https://bit.ly/3RbfQHe
#Amoéba annonce l’annulation de l’émission de la 8° tranche optionnelle d’OCA et la signature d’un contrat avec Redbridge Debt and Treasury Advisory afin d’adapter sa stratégie financière aux enjeux de transformation industrielle

📣 Communiqué de presse : https://bit.ly/3X2hdKt
#Amoéba confirme son éligibilité au dispositif PEA-PME. Les #actions AMOEBA peuvent donc être intégrées dans les portefeuilles PEA PME, dédiés aux #investissements dans les #PME et #ETI selon les critères réglementaires.

🎥 @Fabrice Plasson, PDG d’#Amoéba, revient sur cette année exceptionnelle dans une vidéo dédiée au #bilan 2022 et aux #perspectives 2023. AMM, nouvelle usine, stratégie, plan de financement, tant de sujets abordés sur la chaîne #YouTube d’#Amoéba : https://bit.ly/3Wz75bz

Amoeba withdraws its biocide file in Canada

Amoeba withdraws its biocide file in Canada to focus its resources on strategic priorities 

Lyon (France), October 19, 2022 – 17h45 – AMOÉBA (FR0011051598 – ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, announces that it will not pursue the application for its living amoeba-based biocide in Canada. 

Considering the high regulatory risk of this application, which mobilizes human and financial resources, Amoeba has decided to definitively withdraw the application for registration in Canada and to focus its resources on low regulatory risk applications, mainly the biocontrol application which has received positive evaluations in Europe and in the United States so far (see Press Releases of April 25, 2022 and September 29, 2022 respectively) and the biocidal application in closed cooling towers in the United States (see Press Release of August 10, 2022). 

Amoeba is also pursuing its research and development of other uses of the amoeba, in its non-living lysed form, which presents a much lower regulatory risk than the living form, and therefore a high chance of success.